Vol. 7, Issue 10 (2018)

Materials and Methods: The study took place at the ICARE Institute of Medical Sciences and Research in Haldia, West Bengal, India, in the Department of Pharmacology. From July 2017 to May 2018, the study was done. After getting permission from the Institutional Ethics Committee, patients who were qualified were chosen by randomisation.

Results: 50 people took part in the study, with twenty-five in each group. Both groups had mean ages of 46 years for the glimepiride group (II) and 44 years for the sitagliptin group (I). There was no difference between the groups in terms of age that was statistically significant. The first group had 25 men and 25 women, and the second group had 24 men and 26 women. The occurrence rate was about the same in both groups, and there was no statistical difference between them.

Conclusions: E This study shows that sitagliptin works just as well as glimepiride at better blood sugar control when taken with metformin. It is also well tolerated and doesn't have any major side effects. When compared to glimepiride, sitagliptin has benefits, such as a lower risk of diabetes.